Concepedia
Statistics
Publications
20
Citations
5.9K
H-Index
14
Active since
2002
Affiliations
The University of Texas MD Anderson Cancer Center(Current)
GlaxoSmithKline (United States)
University of Lübeck
University Hospital Schleswig-Holstein
Sir Charles Gairdner Hospital
S. Swann is an author at The University of Texas MD Anderson Cancer Center specializing in oncology, medicine, and pharmacology.
Publications per year
2002–2018
Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial
Axel Hauschild, Jean‐Jacques Grob, Lev Demidov et al. · The Lancet · 2012 · 3K citations
Medicine, Oncology, Pharmacology +11
Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial
Georgina V. Long, Daniil Stroyakovskiy, Helen Gogas et al. · The Lancet · 2015 · 1.4K citations
Medicine, Oncology, Pharmacology +7
Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial
Georgina V. Long, Uwe Trefzer, Michael A. Davies et al. · The Lancet Oncology · 2012 · 908 citations
Medicine, Oncology, Pharmacology +12
Relationships between pazopanib exposure and clinical safety and efficacy in patients with advanced renal cell carcinoma
A. Benjamin Suttle, Howard Ball, Mathiéu Molimard et al. · British Journal of Cancer · 2014 · 184 citations · Full text
Medicine, Oncology, Pharmacology +17
Characteristics of pyrexia in BRAFV600E/K metastatic melanoma patients treated with combined dabrafenib and trametinib in a phase I/II clinical trial
Alexander M. Menzies, Michelle T. Ashworth, S. Swann et al. · Annals of Oncology · 2014 · 89 citations
1–5 of 20